id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-356057-87kxlqdc	Chagas, Aline Lopes	Management of Hepatocellular Carcinoma during the COVID-19 Pandemic - São Paulo Clínicas Liver Cancer Group Multidisciplinary Consensus Statement	2020-10-15		.txt	text/plain	4360	194	45	Patients with hepatocellular carcinoma (HCC) are at an increased risk for severe COVID-19 as they present with two major diseases: cancer and concomitant chronic liver disease. However, during the pandemic, the risks and benefits of HCC treatment should be individualized and factors like tumor stage, liver function, age, comorbidities, local availability of resources, and the risk of SARS-CoV-2 infection should be considered (5, (14) (15) (16) . When a ''bridge treatment'' is chosen, alpha-fetoprotein monitoring and imaging examinations should be performed so that patients are not dropped off the liver transplantation (LT) list and their chances of availing other curative therapies are retained, such as surgery or radiofrequency ablation (RFA). The risks and benefits of performing TACE with SBRT and systemic treatment in patients at a high risk for severe SARS-CoV-2 infection, such as those aged 475 years and/ or having comorbidities, and patients with multifocal tumors (43 nodules), especially those who fall outside the Up-to-7 criteria (25), should be discussed by a multidisciplinary team.	./cache/cord-356057-87kxlqdc.txt	./txt/cord-356057-87kxlqdc.txt